Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Shares Bought by DCF Advisers LLC

Key Points

• DCF Advisers LLC increased its stake in Zai Lab by 39%, acquiring an additional 25,250 shares, bringing their total ownership to 90,000 shares.
• Multiple institutional investors have significantly increased their holdings in Zai Lab, with FMR LLC leading by boosting its stake by 749.1% in the last quarter.
• Analysts have mixed views on Zai Lab, with a consensus rating of "Moderate Buy" and an average price target of $54.28, despite recent downgrades from certain firms.

DCF Advisers LLC increased its position in shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Free Report) by 39.0% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 90,000 shares of the company's stock after purchasing an additional 25,250 shares during the quarter. Zai Lab makes up approximately 1.6% of DCF Advisers LLC's holdings, making the stock its 20th biggest holding. DCF Advisers LLC owned approximately 0.08% of Zai Lab worth $3,253,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. JPMorgan Chase & Co. boosted its stake in shares of Zai Lab by 17.0% in the fourth quarter. JPMorgan Chase & Co. now owns 161,635 shares of the company's stock valued at $4,233,000 after buying an additional 23,510 shares during the period. Pictet Asset Management Holding SA acquired a new position in Zai Lab in the fourth quarter valued at about $31,000. Orion Portfolio Solutions LLC bought a new stake in Zai Lab during the fourth quarter worth about $313,000. Geode Capital Management LLC increased its holdings in Zai Lab by 27.3% in the 4th quarter. Geode Capital Management LLC now owns 55,520 shares of the company's stock valued at $1,454,000 after buying an additional 11,894 shares during the period. Finally, Wells Fargo & Company MN raised its position in shares of Zai Lab by 8,090.8% in the 4th quarter. Wells Fargo & Company MN now owns 40,954 shares of the company's stock valued at $1,073,000 after buying an additional 40,454 shares in the last quarter. 41.65% of the stock is currently owned by institutional investors.

Insider Activity at Zai Lab

In other news, Director William Lis sold 13,814 shares of Zai Lab stock in a transaction that occurred on Friday, June 20th. The shares were sold at an average price of $35.67, for a total transaction of $492,745.38. Following the sale, the director owned 35,106 shares in the company, valued at $1,252,231.02. This trade represents a 28.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Yajing Chen sold 9,618 shares of the business's stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $30.00, for a total transaction of $288,540.00. Following the transaction, the chief financial officer owned 17,429 shares in the company, valued at $522,870. This trade represents a 35.56% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 160,155 shares of company stock worth $4,959,535. 4.96% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several research firms have weighed in on ZLAB. Leerink Partners set a $75.00 target price on Zai Lab and gave the stock an "outperform" rating in a research note on Monday, June 30th. Wall Street Zen lowered Zai Lab from a "buy" rating to a "hold" rating in a research note on Friday, June 27th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, Zai Lab has a consensus rating of "Moderate Buy" and a consensus target price of $54.28.

Zai Lab Stock Performance

ZLAB traded down $5.13 during midday trading on Thursday, hitting $33.59. The stock had a trading volume of 697,963 shares, compared to its average volume of 999,499. The business has a fifty day moving average of $36.48 and a 200 day moving average of $33.09. The company has a market cap of $3.73 billion, a P/E ratio of -13.43 and a beta of 1.03. Zai Lab Limited Unsponsored ADR has a 1 year low of $16.01 and a 1 year high of $44.34.

Zai Lab (NASDAQ:ZLAB - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.42) by $0.05. Zai Lab had a negative return on equity of 33.35% and a negative net margin of 60.26%. On average, equities research analysts anticipate that Zai Lab Limited Unsponsored ADR will post -2.58 earnings per share for the current year.

Zai Lab Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.